Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04768-x
Several deaths during trials of experimental cell and gene therapies in China appear to reveal gaps in governance and oversight. A new layer of independent external review is needed for clinical supervision of high-risk therapies.
